Pulse

What Pulse does

Pulse Pharmaceuticals is a privately held, vertically integrated Indian pharmaceutical company founded in 1997 and headquartered in Hyderabad, with manufacturing operations in Roorkee, Uttarakhand, and a dedicated R&D center, PARC, established in Hyderabad in 2010. The company develops, manufactures, and markets branded generic pharmaceutical and nutraceutical products organized into seven therapeutic divisions covering women's and child health, neurology and mental health, cardiometabolic disorders, bone and joint health, chronic pain, autoimmune disorders, and clinical nutrition. Its technology base rests on five proprietary drug-delivery platforms — AQUEOL, LYO MATRIX, INVERSOL, IGNATE, and PERMIAL — applied through five specialized R&D sub-divisions (NR&D, AR&D, FR&D, PR&D, GCTR&D) to improve bioavailability, taste masking, and targeted delivery, with a newer GCTR&D unit at the Atal Incubation Centre – CCMB focused on gene and cell therapies.

The company operates a multi-tier domestic distribution network of 21 C&F agents, 750+ authorized dealers and stockists, and 150,000+ retail and hospital pharmacies, supported by a field force of 1,000+ employees that engages 100,000+ healthcare professionals. Internationally, Pulse markets directly and through strategic partnerships across South East Asia, GCC, LATAM, Russia & CIS, and Africa. Manufacturing is anchored by a WHO-GMP-certified Roorkee facility accredited by NAFDAC, Philippines FDA, Ghana, Kenya, Zimbabwe, Sri Lanka, and Uganda regulators, with USFDA-quality standards applied to clinical nutrition products and an active renovation program targeting EU-GMP qualification.

The revenue model is B2B pharmaceutical manufacturing and marketing through institutional distribution channels; pricing is negotiated privately with no public price disclosures. The portfolio spans 90+ branded SKUs across the seven divisions, and the leadership team is dominated by the founding family (Founder & Managing Director K V Rambabu and family-member directors) supplemented by functional directors and a Chief Scientific Officer for Cell Therapeutics. The company is privately held with no disclosed institutional investors, funding rounds, or M&A history, indicating growth has been organically funded through operations.

Name

Pulse

Legal name

Pulse Pharmaceuticals

Website

https://pulsepharma.net

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Pulse Pharmaceuticals is a privately held, vertically integrated Indian pharmaceutical company that develops, manufactures, and markets branded generic and nutraceutical products across seven therapeutic divisions, distributing through 150,000+ Indian pharmacies and exporting to South East Asia, GCC, LATAM, Russia & CIS, and Africa.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical manufacturing
• Branded generics
• Drug delivery technology
• Nutraceutical products
• Specialty formulations

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Pharmaceutical Products Manufacturing & Marketing: Develops and manufactures high-quality pharmaceutical products targeting various therapeutic areas including pain management, neurology, cardiometabolic disorders, bone & joint health, women's health, and clinical nutrition. Markets products directly or through strategic partnerships across various geographies.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels2 records

Core offering

Pulse Pharmaceuticals is an integrated Indian pharmaceutical company that develops, manufactures and markets branded generic and specialty pharmaceutical and nutraceutical products across six therapeutic divisions (Nucleus, Stimulus, Impetus, Maximus, Gladius, Immunus, Nutrius). Its portfolio spans chronic pain management, neurology, cardiometabolic disorders, bone and joint health, women's and child health, autoimmune disorders and clinical nutrition. The company leverages proprietary drug delivery technologies (AQUEOL, LYO MATRIX, INVERSOL, IGNATE, PERMIAL) developed at its in-house R&D center (PARC) to produce differentiated nano-therapeutic and nutri-therapeutic formulations with enhanced bioavailability and patient compliance.

Product overview

Pulse Pharmaceuticals is an integrated Indian pharmaceutical company founded in 1997, operating as a multi-divisional portfolio organization. The company manufactures and markets a diverse range of pharmaceutical and nutraceutical products organized across six therapeutic divisions: GLADIUS (chronic pain management), IMMUNUS (autoimmune disorders), MAXIMUS (bone and joint health), IMPETUS (cardiometabolic disorders), NUCLEUS (women's and child health), and STIMULUS (epilepsy, sleep, and depression). The product portfolio includes branded generics across multiple therapy segments including diabetic neuropathy, osteoporosis, muscle relaxants, vitamins and supplements, antiepileptics, antidepressants, and anticoagulants. The company's innovation strategy is anchored by PARC (Pulse Advanced Research Center) with five specialized R&D sub-divisions (NR&D, AR&D, FR&D, PR&D, GCTR&D) developing proprietary drug delivery technologies including AQUEOL, LYO MATRIX, INVERSOL, IGNATE, and PERMIAL, enabling the creation of differentiated nano-therapeutic and nutri-therapeutic products with enhanced bioavailability and patient compliance. Manufacturing operations are conducted at WHO-GMP certified facilities in Roorkee and Hyderabad, with products distributed across domestic, institutional, and export markets.

Differentiator

Problem solved

Functional benefit

Brands

• PARC (Pulse Advanced Research Center): State-of-the-art R&D facility in Hyderabad dedicated to developing innovative pharmaceutical products and proprietary drug delivery technologies.
• Nucleus
• Stimulus
• Impetus
• Maximus
• Gladius
• Immunus
• Nutrius

Products and services

• Gladius - Chronic Pain Management Division Specialty pharmaceutical products for chronic pain management including neuropathic pain, muscle relaxants, anti-inflammatory drugs and diabetic neuropathy treatments sold through pharmacy and institutional channels.
• Stimulus - Neurology & Mental Health Division Pharmaceutical products for neurology and mental health including anticonvulsants for epilepsy, antidepressants for depression, sleep aids and vestibular treatments prescribed by neurologists and psychiatrists.
• Impetus - Cardiometabolic Disorders Division Pharmaceutical products for cardiometabolic conditions including cholesterol management, anticoagulation, vitamin D supplementation and diabetes-related cardiovascular care.
• Maximus - Bone & Joint Health Division Pharmaceutical and nutraceutical products for osteoporosis, osteoarthritis, bone health and fracture healing including calcium supplements, anti-inflammatory formulations and joint care products.
• Nucleus - Women & Child Health Division Pharmaceutical and nutraceutical products for women's health, pregnancy support, child nutrition, anemia treatment and postnatal care.
• Immunus - Autoimmune Disorders Division Specialty pharmaceutical products for autoimmune disorders and rheumatology, including immunomodulators and targeted therapies.
• Nutrius - Clinical Nutrition Division Clinical and enteral nutrition products including vitamin D supplements, multivitamin formulations and nutritional supplements manufactured under WHO-GMP and USFDA quality standards.
• PARC - Pulse Advanced Research Center State-of-the-art in-house R&D facility in Hyderabad with five specialized sub-divisions (NR&D, AR&D, FR&D, PR&D, GCTR&D) developing novel drug delivery technologies and gene/cell therapies.
• Gene and Cell Therapeutics R&D (GCTR&D) Division Gene and cell therapy research and development for rare and life-threatening diseases, leveraging CCMB incubation infrastructure.

Named customers1 record

Segments7 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Atal Incubation Centre – CCMB (Hyderabad)coreStrategic or Co-development PartnerPulse's Gene and Cell Therapeutics Research & Development division (GCTR&D) is located at Atal Incubation Centre – CCMB, dedicated to developing and commercializing gene and cell therapies for patients traumatized by rare and life-threatening diseases. The partnership leverages CCMB's incubation infrastructure and scientific expertise for advanced biotech research.

Scale indicators4 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Eris Lifesciences: Indian mid-sized specialty pharma focused on chronic and super-specialty therapeutic segments (cardiology, diabetology, neurology, women's health, bone & joint) with a strong field force model and branded-generic strategy — directly comparable in portfolio structure, channel model and patient-facing chronic-disease focus to Pulse's seven therapeutic divisions.
• Ajanta Pharma: Indian specialty pharma with branded formulations across cardiology, dermatology, ophthalmology and emerging-market exports (Africa, Asia, CIS). Comparable to Pulse's mix of specialty chronic-care brands plus emerging-market export orientation and multi-country regulatory accreditations.
• JB Chemicals & Pharmaceuticals: Indian pharma with a portfolio spanning cardiology, nephrology, anti-infectives and vitamins with strong domestic field-force coverage and exports to Africa and CIS. Comparable therapeutic breadth, India distribution depth and emerging-market presence to Pulse.
• Alkem Laboratories: Indian specialty/generic pharma with therapeutic areas including neuro-psychiatry, cardiology, anti-infectives, pain and nutrition. Comparable multi-therapeutic branded-generic strategy, pan-India field sales force and emerging-market exports to Pulse's model.
• Torrent Pharmaceuticals: Indian specialty pharma with strong franchises in cardiology, CNS, gastro and chronic disease segments plus significant international presence including emerging markets. Comparable specialty therapy mix and branded-generic commercial model to Pulse.
• Glenmark Pharmaceuticals: Indian specialty pharma with branded generics and proprietary drug-delivery platforms across dermatology, respiratory, oncology and cardiology. Comparable to Pulse on branded-generic model, India field-force scale and proprietary technology emphasis.
• Strides Pharma Science: Indian pharma focused on generic formulations and emerging-market (Africa, SE Asia) distribution with regulated-market ambitions. Comparable to Pulse's emerging-market export footprint and WHO-GMP-certified manufacturing base.
• Emcure Pharmaceuticals: Indian pharma with diversified therapeutic portfolio (cardiology, anti-infectives, neurology, gynecology), strong domestic field force and exports to emerging markets. Comparable in portfolio breadth, distribution model and India-manufacturing-base orientation.

Broad incumbents

• Cipla: One of India's largest pharma companies with extensive respiratory, cardiology, anti-infective and chronic-disease franchises plus global manufacturing footprint. Overlaps with Pulse on multiple therapeutic segments and emerging-market exports but operates at significantly larger scale and includes API/inhalers/biologics.
• Lupin: Major Indian specialty/generic pharma with franchises in cardiology, CNS, diabetes and women's health plus USFDA-approved manufacturing. Comparable therapeutic segments to Pulse but operates globally with significantly larger R&D and capital base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Pulsepharmaltd
• Facebookfacebook.com/pulsepharmapvtltd
• LinkedInlinkedin.com/company/pulse-pharmaceuticals

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pulse